Mohammad
Noshad

The resulting product - also called Shyld AI - can inactivate MRSA pathogens in 10 seconds from 6.5 feet away. It operates on a field of view that covers 6 to 8 feet and completes full surface disinfection in 20 to 60 seconds. Unlike traditional UV-C systems, it uses LED-based UV-C rather than mercury vapor lamps, eliminating material degradation and toxic off-gassing. It can run while a room is occupied, targeting aerosols and droplets in overhead space that humans never reach with a mop.

That last detail matters more than it sounds. Hospital-acquired infections kill tens of thousands of patients per year in the United States. The annual cost to the healthcare system exceeds $50 billion. Most of that burden comes not from catastrophic lapses in hygiene but from the mundane impossibility of disinfecting every surface in every room between every use - especially when a room turns over in under an hour. Shyld AI doesn't solve the problem by getting humans to clean better. It removes humans from the equation entirely.

Stanford Health Care was an early believer. A pilot that began with a handful of units expanded to more than 20 across the facility. Loma Linda University Medical Center followed. A peer-reviewed study published in ScienceDirect in 2025 validated the system's effectiveness in endoscopy units - one of the most infection-prone environments in any hospital.

The business model is structured to remove another barrier: hospitals pay no upfront hardware cost. Shyld AI operates on a subscription model starting at $200 per device per month, with pricing tiers based on volume and contract length. It's a SaaS structure applied to physical hardware - a choice that reflects Noshad's understanding of how hospital procurement actually works.

Noshad also runs Wodio.AI, a generative AI engagement platform he co-founded. He serves as a Strategic Advisor at Field AI. The parallel ventures point to an entrepreneur who thinks systematically about where AI has yet to reach operational deployment - and then tries to get there before the market has finished deliberating.

With $14 million raised from Demos Capital, Plug and Play Tech Center, and Camford Capital, FDA approval pending as of early 2025, and partnerships including Shimadzu on the hardware side and Seal Shield on distribution, Shyld AI is moving from pilot to platform. Noshad's stated goal: 40+ hospitals in the US and internationally within the next year.

The device on the ceiling will keep getting smarter. That's the part he's most focused on - not just cleaning, but continuous ambient monitoring, real-time pathogen scoring, and AI-driven protocols that respond to what's actually happening in a room rather than what a cleaning checklist assumes. Infection control as a data problem. Mohammad Noshad figured out the hardware. Now he's working on the intelligence layer.